This is not the most recent version of the article. View current version (15 DEC 2016)

Intervention Review

Risperidone versus placebo for schizophrenia

  1. Ranganath D Rattehalli1,*,
  2. Mahesh B Jayaram2,
  3. Michael Smith3

Editorial Group: Cochrane Schizophrenia Group

Published Online: 20 JAN 2010

Assessed as up-to-date: 4 FEB 2008

DOI: 10.1002/14651858.CD006918.pub2


How to Cite

Rattehalli RD, Jayaram MB, Smith M. Risperidone versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD006918. DOI: 10.1002/14651858.CD006918.pub2.

Author Information

  1. 1

    Millfield House, Leeds, UK

  2. 2

    Leeds Partnership Foundation NHS Trust, CMHT, Leeds, UK

  3. 3

    Leeds Partnership Foundation Trust, Child and Adolescent Psychiatry, Leeds, UK

*Ranganath D Rattehalli, Millfield House, Kirk Lane, Leeds, LS19 7LX, UK. rdrattehalli@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 20 JAN 2010

SEARCH

This is not the most recent version of the article. View current version (15 DEC 2016)

  1. Current Version

    Risperidone versus placebo for schizophrenia

    Ranganath D Rattehalli, Sai Zhao, Bao Guo Li, Mahesh B Jayaram, Jun Xia and Stephanie Sampson

    Version of Record online: 15 DEC 2016 | DOI: 10.1002/14651858.CD006918.pub3

Previous versions of this article and their online publication dates

  1. Version 2

    Risperidone versus placebo for schizophrenia

    Ranganath D Rattehalli, Mahesh B Jayaram and Michael Smith

    Version of Record online: 20 JAN 2010 | DOI: 10.1002/14651858.CD006918.pub2

  2. Version 1

    Risperidone versus placebo for schizophrenia

    Ranganath Rattehalli and Mahesh B Jayaram

    Version of Record online: 23 JAN 2008 | DOI: 10.1002/14651858.CD006918